These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15120098)

  • 1. Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.
    Kamakura K; Mochizuki H; Kaida K; Hirata A; Kanzaki M; Masaki T; Nakamura R; Motoyoshi K
    Parkinsonism Relat Disord; 2004 Jun; 10(4):235-42. PubMed ID: 15120098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
    Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
    Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E; González M; Aguilar A; Quintana S
    Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term experience with selegiline and levodopa in Parkinson's disease.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Ozekmekçi S; Apaydin H; Kiliç E
    Clin Neurol Neurosurg; 2005 Jun; 107(4):306-9. PubMed ID: 15885389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times.
    Zhao YJ; Wee HL; Au WL; Seah SH; Luo N; Li SC; Tan LC
    Parkinsonism Relat Disord; 2011 Mar; 17(3):194-7. PubMed ID: 21159539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term selegiline tolerance in the treatment of Parkinson's disease].
    Vermersch P; Petit H
    Therapie; 1992; 47(1):75-8. PubMed ID: 1523599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
    Goetz CG; Wuu J; Curgian L; Leurgans S
    Mov Disord; 2006 Feb; 21(2):267-70. PubMed ID: 16161144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
    Winge K; Werdelin LM; Nielsen KK; Stimpel H
    Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of hallucinations in Parkinson's disease using a novel scale.
    Wada-Isoe K; Ohta K; Imamura K; Kitayama M; Nomura T; Yasui K; Nakaso K; Nakashima K
    Acta Neurol Scand; 2008 Jan; 117(1):35-40. PubMed ID: 18095953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 18. Hallucinations in Parkinson's disease--a study of forty three patients.
    Gupta M; Singh G; Khwaja GA; Mehndiratta MM
    J Assoc Physicians India; 2004 Sep; 52():703-6. PubMed ID: 15839446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.